Switching of anti-TNF-α agents in Behçet's disease

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Furuta, Shunsuke ^a   Chow, Yok Wai ^b   Chaudhry, Afzal N ^a   Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b Pantai Hospital Ayer Keroh   (Malaysia)

Author keywords

Adalimumab; Anti TNF agent; Beh et's disease; Etanercept; Infliximab

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; RITUXIMAB; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALOPECIA; ARTHROPATHY; ARTICLE; BASAL CELL CARCINOMA; BEHCET DISEASE; CASE STUDY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROPATHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; LIVER FUNCTION; LYMPHATIC LEUKEMIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; UVEITIS; DRUG ANTAGONISM; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT FAILURE;

ADULT; BEHCET SYNDROME; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84873273535     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. SAKANE T, TAKENO M, SUZUKI N, INABA G: Behçet's disease. N Engl J Med 1999; 341: 1284-91.
2. YAZICI Y, YURDAKUL S, YAZICI H: Behçet's syndrome. Curr Rheumatol Rep 2010; 12: 429-35.
3. DEMENTHON M, LAVALLEY MP, MALDINI C, GUILLEVIN L, MAHR A: HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009; 61: 1287-96.
4. KANEKO S, SUZUKI N, YAMASHITA N et al.: Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet's disease (BD) in Japan. Clin Exp Immunol 1997; 108: 204-12.
5. YAMASHITA N, KANEOKA H, KANEKO S et al.: Role of cd T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997; 107: 241-7.
6. MEGE JL, DILSEN N, SANGUEDOLCE V et al.: Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-9.
7. FRASSANITO MA, DAMMACCO R, CAFFORIO P et al.: Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999; 42: 1967-74.
8. MELIKOGLU M, FRESKO I, MAT C et al.: Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.
9. SFIKAKIS PP, MARKOMICHELAKIS N, ALP-SOY E et al.: Review Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007; 46: 736-41.
10. ARIDA A, FRAGIADAKI K, GIAVRI E, SFIKAKIS PP: Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 Patients. Semin Arthritis Rheum 2011; 41: 61-70.
11. INTERNATIONAL STUDY GROUP FOR BEHçET'S DISEASE: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
12. HATEMI G, SILMAN A, BANG D et al.; EULAR EXPERT COMMITTEE: EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-62.
13. BHAKTA BB, BRENNAN P, JAMES TE, CHAM-BERLAIN MA, NOBLE BA, SILMAN AJ: Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38: 728-33.
14. WOLBINK GJ, VIS M, LEMS W et al.: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
15. BARTELDS GM, WIJBRANDTS CA, NURMO-HAMED MT et al.: Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
16. KIEVIT W, FRANSEN J, ADANG EM et al.: Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: result from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011; 50: 196-203.
17. GLADMAN DD, MEASE PJ, RITCHLIN CT et al.: Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56: 476-88.
18. SMOLEN JS, EMERY P: Infliximab: 12 years of experience. Arthritis Res Ther 2011; 13 (Suppl. 1): S2.
19. HYRICH KL, LUNT M, WATSON KD, SYM-MONS DP, SILMAN AJ: British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor S-68 necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20.
20. BOOTH A, HARPER L, HAMMAD T et al.: Prospective study of TNF-αlpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717-21.
21. WEGENER'S GRANULOMATOSIS ETANERCEPT TRIAL (WGET) RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.
22. OLIVIERI I, LECCESE P, D'ANGELO S et al.: Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S54-7.
23. IWATA S, SAITO K, YAMAOKA K et al.: Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 2011; 21: 184-91.
24. TOGNON S, GRAZIANI G, MARCOLONGO R: Anti-TNF-αlpha therapy in seven patients with Behçet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci 2007; 1110: 474-84.
25. HANDA T, TSUNEKAWA H, YONEDA M et al.: Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S58-63.
26. KIKUCHI H, ARAMAKI K, HIROHATA S: Effect of infliximab in progressive neuro-Behçet's syndrome. J Neurol Sci 2008; 272: 99-105.
27. CALVO CATALá J, CAMPOS FERNáNDEZ C, RUEDA CID A, GONZáLEZ-CRUZ CERVEL-LERA MI, BAIXAULI RUBIO A, PASTOR CU-BILLO MD: Efficacy of adalimumab in Behçet's disease. Description of 6 cases. Rheu-matol Clin 2011; 7: 258-61.
28. ISHIGATSUBO Y, SAMUKAWA S: Behçet's disease from the aspect of autoinflammatory disease. Nihon Rinsho Meneki Gakkai Kaishi 2011; 34: 408-19.
29. NAM JL, WINTHROP KL, VAN VOLLENHOVEN RF et al.: Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a sys-tematic literature review informing the EU-LAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-86.
30. SOLIMAN MM, ASHCROFT DM, WATSON KD, LUNT M, SYMMONS DP, HYRICH KL; BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER: Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthri-tis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 583-9.